UBS’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
Sell
-800
Closed -$13K 11428
2014
Q2
$13K Sell
800
-400
-33% -$5.88K ﹤0.01% 8662
2014
Q1
$16K Buy
1,200
+100
+9% +$1.56K ﹤0.01% 8428
2013
Q4
$18K Sell
1,100
-5,300
-83% -$84.5K ﹤0.01% 8324
2013
Q3
$106K Buy
6,400
+5,400
+540% +$79.8K ﹤0.01% 5957
2013
Q2
$10K Buy
+1,000
New +$10.5K ﹤0.01% 8696

Other funds holding OSIR

UBS's OSIR Position: Q3 2014 in Review

UBS increased its Osiris Therapeutics, Inc. Common Stock (OSIR) stake by 512% in Q3 2014, buying an estimated $117K and bringing the position to 9,799 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #5755.

UBS first reported a position in OSIR in Q2 2013 and has held it in 6 quarters since. The position peaked at $292K in Q3 2013. 67 funds tracked by Wall St. Rank hold OSIR as of Q3 2014.

  • UBS held 9,799 shares of Osiris Therapeutics, Inc. Common Stock worth $123K as of Q3 2014.
  • UBS bought 8,199 Osiris Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $117K.
  • Osiris Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #5755 holding.
  • UBS first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Osiris Therapeutics, Inc. Common Stock position peaked at $292K in Q3 2013.
  • 67 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.